Cas:885279-60-7 tert-butyl N-[2-(5-bromothiophen-2-yl)ethyl]carbamate manufacturer & supplier

Chemical Name:tert-butyl N-[2-(5-bromothiophen-2-yl)ethyl]carbamate

CAS.NO:885279-60-7

Synonyms:QC-7852;tert-Butyl (2-(5-bromothiophen-2-yl)ethyl)carbamate

Molecular Formula:C₁₁H₁₆BrNO₂S

Molecular Weight:306.21900

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:66.57000

Exact Mass:305.00900

LogP:3.96870

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like QC-7852 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tert-Butyl (2-(5-bromothiophen-2-yl)ethyl)carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,QC-7852 Use and application,QC-7852 technical grade,usp/ep/jp grade.

Related News: Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). tert-butyl N-[2-(5-bromothiophen-2-yl)ethyl]carbamate manufacturer Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. tert-butyl N-[2-(5-bromothiophen-2-yl)ethyl]carbamate supplier On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday. tert-butyl N-[2-(5-bromothiophen-2-yl)ethyl]carbamate vendor Compared with individuals with cancer only, those with ASCVD and with ASCVD and cancer had a significantly higher presence of three of more of these factors (23 and 30 percent, respectively, versus 13 percent). tert-butyl N-[2-(5-bromothiophen-2-yl)ethyl]carbamate factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.